Antibody to reduce skin inflammation and epidermal hyperplasia in psoriasis-like autoimmune disease
減少皮膚炎症和表皮的抗體 銀屑病樣自身免疫性疾病中的增生
CA mAbs modulate macrophage polarization from M1-like (pro-inflammation, damaging) toward M2-like (anti-inflammation, repairing) phenotypes to suppress
systemic inflammation and ameliorate psoriasis-like symptoms.
CA mAb 調節巨噬細胞從 M1 樣（促炎症、破壞性）表型到 M2 樣（抗炎、修復）表型的極化以抑制全身炎症和改善牛皮癬樣症狀。
Targeted indication
Psoriasis-like autoimmunediseases.
Suppress inflammation, reducing
TNF-α, IL-17A and IL-23 levels.
Status
Monoclonal Abs available; Animal mouse model
Key features
- Anti-inflammation: Modulate monocyte/macrophage polarization from M1 to M2.
- IP or IV injection, a simple and efficient method.
- Much less mAb required (1/10 to 1/30 of regular dose). Safe, less ADCC.
Market
Therapy for inflammatory related diseases, including psoriasis, and brain and other systemic inflammatory related diseases.
Market for Ab drugs to inhibit inflammation: more than US$40 billion/year.
Suppressing of IL-17A, IL-23 and TNF-α: therapy for autoimmune diseases.
Modulation of macrophage polarization from pro-inflammatory (M1-like) toward anti-inflammatory (M2-like) phenotypes to curb inflammation has become an important approach clinically, including brain diseases, while the effect remains unsatisfactory.
CA mAb-modified macrophages will migrate into brain and tissues to suppress local inflammation.
Less Ab required may reduce side effects such as ADCC.
MODE OF ACTION
EXPERIMENTAL RESULTS
CA mAb suppresses iNOS and pro-inflammatory cytokine production in bone marrow-derived macrophages.
IP injection of CA mAb suppresses IMQ-induced cytokine expression and epidermal hyperplasia in psoriasis model.
Much less mAb required (0.5 mg/kg, compared with 10 to 30 mg/kg in other mouse study), expecting to have less ADCC (Ab-dependent cellular cytotoxicity)
Ab will not bind to non-immune cells: less side-effects.
Four mAbs available and sequenced. Two of them have been tested to have therapeutic efficacy.
Recombinant CA mAbs have been tested in psoriasis model with therapeutic efficacy.
INTELLECTUAL PROPERTY
BUSINESS OPPORTUNITY
Licensing and/or Collaboration, Sponsored Research
CONTACT
service@biip-dcc.org